Furthermore, we developed a nomogram that integrated the risk signature with clinicopathological factors (IDH1 status, age and experience of radiotherapy or chemotherapy) and validated its better performance for predicting 1‐, 3‐ and 5‐year survival rate of GBM patients. This evidence concerns the gene IDH1 and glioblastoma.